Citigroup’s NRX Pharmaceuticals NRXP Stock Holding History

Citigroup’s Portfolio NRXP Stock Details NRXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$24.5K	Buy	+5,992	New	+$19.8K	﹤0.01%	5124
2025 Q1	–	Sell	-593	Closed	-$1.3K	–	5832
2024 Q4	$1.3K	Buy	+593	New	+$797	﹤0.01%	5576
2022 Q4	–	Sell	-876	Closed	-$6K	–	5897
2022 Q3	$6K	Buy	876 +778	+794%	+$5.24K	﹤0.01%	5177
2022 Q2	$1K	Sell	98 -1,423	-94%	-$18.7K	﹤0.01%	6065
2022 Q1	$37K	Buy	1,521 +1,187	+355%	+$38.6K	﹤0.01%	4863
2021 Q4	$16K	Buy	334 +286	+596%	+$20.6K	﹤0.01%	5453
2021 Q3	$4K	Buy	48 +39	+433%	+$5.07K	﹤0.01%	5610
2021 Q2	$1K	Buy	+9	New	+$2.38K	﹤0.01%	6047

Other funds holding NRXP

BGI

B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citigroup's NRXP Position: Q2 2026 in Review

Citigroup opened a new position in NRX Pharmaceuticals (NRXP) in Q2 2026: 5,992 shares worth $24.5K. The stake represents ﹤0.01% of the portfolio and ranks #5124 among its holdings. This is a return to the name: Citigroup previously reported a position in NRXP as recently as Q4 2024.

Citigroup first reported a position in NRXP in Q2 2021 and has held it in 8 quarters since. The position peaked at $37K in Q1 2022. 47 funds tracked by Wall St. Rank hold NRXP as of Q2 2026.

Citigroup held 5,992 shares of NRX Pharmaceuticals worth $24.5K as of Q2 2026.
NRX Pharmaceuticals was a new Citigroup position in Q2 2026.
NRX Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #5124 holding.
Citigroup first reported a position in NRX Pharmaceuticals in Q2 2021 and has held it in 8 quarters since.
Citigroup's NRX Pharmaceuticals position peaked at $37K in Q1 2022.
47 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.